The Courier is responsible for the safe, timely and compliant transport of materials, including biological materials, such as plasma, live tissue, and related substances, between company facilities and designated partner locations. This role supports operational efficiency by ensuring reliable courier services across SAB sites and other locations within the Greater Sioux Falls, SD area.
This is a part-time position with flexible scheduling based on operational needs. The role requires a high level of reliability, professionalism, and adherence to safety standards.
This position does not have supervisory responsibilities.
Work Environment and Travel:
While performing the duties of this job, the employee is regularly required to drive for extended periods of time and also have the ability walk, stand, and sit. The employee must also be able to regularly lift and/or move up to 10 pounds and occasionally lift and/or move up to 25 pounds.
The employer will make reasonable accommodations in compliance with the Americans with Disabilities Act of 1990.
This job description will be reviewed periodically as duties and responsibilities change with business necessity. Primary and additional duties and responsibilities are subject to modification.
SAB BIO is an Equal Opportunity Employer and prohibits discrimination and harassment of any kind. SAB BIO is committed to the principle of equal employment opportunity for all employees and does not discriminate based on race, religion, color, sex, gender identify, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other legally protected status. EOE/AA/Vets

At SAB BIO, our mission is to dramatically redefine what it means to be diagnosed with type 1 diabetes (T1D) by developing a medicine to change the course of disease, not just treat symptoms.
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company was founded in 2014 and traded on Nasdaq (SABS) since 2021.
Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma.
To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies.
SAB BIO’s lead product candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.